Heterocyclic Compounds

Matches 351 - 400 out of 36,990	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/022434A1	PYRIDOCYCLOHEPTANE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF The present application relates to a substituted pyridocycloheptane derivative, a preparation method therefor, and use of a pharmaceutical composition comprising the derivative or a deuterated derivative in medicine. In particular, the p...
WO/2024/026500A2	INHIBITORS OF PDE11A4 AND METHODS OF USING SAME PDE11A4 inhibitors, and methods of using the same, are provided for treating or preventing diseases or disorder associated with cognitive decline.
WO/2024/026290A1	NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS The present invention relates to compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions of the compounds, or salts thereof, that can inhibit secreted phospholipases A2 (sPLA2-X) enzymes, wherein th...
WO/2024/026338A1	N-HETEROCYLIC GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.
WO/2024/026359A1	COMPOUNDS AND METHODS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH PARASITIC WORMS In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that are inhibitors for thioredoxin glutathione reductase (TGR), which is key for ...
WO/2024/022266A1	HETEROARYL COMPOUNDS AS INHIBITORS OF USP1 The disclosure is related to a series of novel heteroaryl derivatives as USP1 inhibitors useful for the treatment of diseases or conditions, such as cancers, especially cancers with BRCA mutations or HR deficiencies. Specifically, provid...
WO/2024/022365A1	WNT PATHWAY INHIBITOR COMPOUND The present invention relates to a Wnt pathway inhibitor compound represented by formula (I), a pharmaceutical composition comprising the compound, and use of the compound of formula (I) in preventing and/or treating cancers, tumors, inf...
WO/2024/022433A1	PRMT5 INHIBITORS Provided is a class of PRMT5 inhibitors represented by formula (X) or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates thereof. Further provided are a preparation ...
WO/2024/025393A1	NOVEL SALT OF IMIDAZO[1,2-A]PYRIDINE COMPOUND, CRYSTALLINE FORM THEREOF, AND PREPARATION METHOD The present invention relates to a novel salt of an imidazo[1,2-a]pyridine compound, a crystalline form thereof, and a preparation method, the novel salt being azetidin-1-yl{8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimid azo[1,2-a]pyridi...
WO/2024/023666A1	CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR This application relates to crystalline forms of an inhibitor of AKR1C3 dependent KARS. (Formula I)
WO/2024/026081A1	TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
WO/2024/023266A1	NOVEL COMPOUNDS The present invention relates to novel compounds for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a component of th...
WO/2024/021957A1	PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF The present invention relates to a PRMT5 inhibitor, a preparation method therefor, and a pharmaceutical use thereof. In particular, the present invention relates to a PRMT5 inhibitor having a compound structure shown in formula (I), a pr...
WO/2024/026410A2	NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) INHIBITORS AND METHODS USING SAME The present disclosure relates to compounds which inhibit one or more members of the neurotrophic receptor tyrosine kinase (NTRK) family (i.e., NTRK1, NTRK2, and/or NTRK3), and pharmaceutical compositions thereof. In another aspect, the ...
WO/2024/017863A1	NOVEL PYRIMIDINYL AND TRIAZINYL SULFONAMIDE DERIVATIVES The invention relates to novel compounds having the general formula (I) wherein R4, R5, X1, X2, X3 and Y1 are as described herein, composition including the compounds and methods of using the compounds.
WO/2024/017856A1	NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES The invention relates to novel compounds having the general formula I wherein R1, R2, X1, X2,X3 and W are as described herein, composition including the compounds and methods of using the compounds.
WO/2024/020517A1	3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITR ILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER Provided herein are compounds of formula (II) and formula (I) that are inhibitors of QPCTL and QPCT: (II) & (I) Also provided are pharmaceutical compositions comprising the compounds, as well as the compounds for use in methods for the t...
WO/2024/020380A1	QUINAZOLINE COMPOUNDS AND METHODS OF USE Substituted quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspects,...
WO/2024/017131A1	HETEROARYLOPIPERIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF The present invention belongs to the field of medicine, and in particular relates to a heteroarylopiperidine derivative, and a pharmaceutical composition and the use thereof. The heteroarylopiperidine as represented by formula (I) provid...
WO/2024/018403A1	SUBSTITUTED IMIDAZOAMIDE COMPOUNDS, AND METHODS USING SAME The present disclosure includes substituted imidazoamide compounds of Formula (I), analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the disclosure can be used to treat, ameliorate, and...
WO/2024/017227A1	SUBSTITUTED FUSED RING CANNABINOID RECEPTOR COMPOUND AND USE THEREOF Provided is a cannabinoid receptor compound as represented by formula I. The compound has a good ability to bind to the human CB2 receptor, and exhibits good agonistic activity and high selectivity on the CB2 receptor. Consequently, said...
WO/2023/250157A9	INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE Disclosed are compounds for inhibiting lipoamide dehydrogenase (Lpd), and methods of treating tuberculosis.
WO/2024/017144A1	SUBSTITUTED IMIDAZO [1, 2-A] PYRIDINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND PREVENTION OF FIBROSIS Provied are a class of substituted imidazo[1,2-a]pyridine compounds, pharmaceutical compositions containing the same, and use of the compounds in the treatment and prevention of fibrosis.
WO/2024/020419A1	AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE Substituted aza-quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspe...
WO/2024/020084A1	HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 Provided herein are compounds and compositions thereof for modulating IRAK4. In some embodiments, the compounds and compositions are provided for treatment of inflammatory or autoimmune diseases.
WO/2024/020068A1	BACTERIAL TOPOISOMERASE INHIBITORS Disclosed are bacterial topoisomerase inhibitors with antibacterial activity, including against fluoroquinolone-resistant Staphylococcus aureus, comprising structural domains: a) a left-hand side (LHS) usually comprising a fused bicyclic...
WO/2024/017855A1	NOVEL ISOTHIAZOL-3-YL AND ISOXAZOL-3-YL SULFONAMIDE COMPOUNDS The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, X and Y are as described herein, composition including the compounds and methods of using the compounds.
WO/2024/020034A1	CBL-B INHIBITORS AND METHODS OF USE THEREOF Disclosed herein are compounds that are Cbl-b inhibitors having a structure according to Formula (II), and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment ...
WO/2024/017924A1	NLRP3 INHIBITORS The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4 and W are as described herein, composition including the compounds and methods of using the compounds.
WO/2024/018915A1	COMPOUND, LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE The purpose of the present invention is to provide a light-emitting element having excellent luminous efficiency and durability.　The present invention provides a compound which is represented by general formula (1). In general formula ...
WO/2024/017294A1	PREPARATION AND USE OF QUINAZOLINONE DERIVATIVE AS KINASE INHIBITOR Disclosed are a compound represented by formula I, a stereoisomer, deuterated product or pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing same, as well as a use thereof as a BRAF modulator in the prepa...
WO/2024/017201A1	CBL-B INHIBITORS AND METHODS OF USES THEREOF Provided for compounds and methods for modulating or inhibiting CBL-B.
WO/2024/017977A1	IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF Compound are provided which can inhibit ERK5. Also provided are pharmaceutical compositions and medical uses of the same, including the use in treating or preventing conditions such as cancers.
WO/2024/017857A1	NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES The invention relates to novel compounds having the general formula I wherein R1, R2, X1, X2,X3 and W are as described herein, composition including the compounds and methods of using the compounds.
WO/2024/012557A1	ANTI-APOPTOTIC BCL-2 FAMILY PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS Provided herein are anti-apoptotic BCL-2 family protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or m...
WO/2024/015827A1	SOLID FORMS OF A TRIAZINE DERIVATIVE AS CBL-B MODULATOR The present disclosure provides, in part, provides crystalline forms of the compound of formula (I). Also provided are pharmaceutical compositions including a crystalline form of the compound of formula (I), as well as the crystalline fo...
WO/2024/012409A1	COMPOUNDS AS MYT1 INHIBITORS Disclosed in the present invention are compounds as MYT1 inhibitors. Particularly, the present invention relates to compounds represented by general formula (1) and a preparation method therefor, as well as the use of the compounds of ge...
WO/2024/012512A1	CARBAZOLE DERIVATIVE AND ORGANIC LIGHT-EMITTING ELEMENT HAVING SAME Provided are a carbazole derivative and a use thereof. The structural formula of the carbazole derivative is as shown in formula (I), and the carbazole derivative has a condensed carbazole structure. The compound can be applied to an org...
WO/2024/012449A1	COMPOUND CONTAINING TRIFLUOROMETHYL GROUP The present application provides a compound containing a trifluoromethyl group, and specifically relates to a compound as represented by formula I-0 or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmace...
WO/2024/012519A1	PAN-KRAS INHIBITOR Provided in the present invention are a fused ring aromatic compound having a broad-spectrum inhibition effect on KRAS mutation, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. As shown in formula ...
WO/2024/011294A1	ANTI-GIARDIAL COMPOUNDS The present disclosure relates to compounds that find application as therapeutics. In particular, the disclosure relates to compounds of Formula (I) or Formula (II) and their pharmaceutically acceptable salt, solvates, or stereoisomers t...
WO/2024/012507A1	BICYCLIC-TYPE MAT2A INHIBITOR AND USE THEREOF Provided are a bicyclic compound represented by formula (I) or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a racemate, an atropisomer, a polymorph, a solvate, or an isotope labeled compound thereof. The compound re...
WO/2023/164234A9	COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing bloo...
WO/2024/012308A1	PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF A PRMT5 inhibitor, a preparation method therefor, and the pharmaceutical use thereof. In particular, the present invention relates to a PRMT5 inhibitor having a structure of formula (I), a preparation method therefor, a pharmaceutical co...
WO/2024/012425A1	HETEROCYCLIC COMPOUND AS RIPK1 INHIBITOR The present invention relates to a compound, a pharmaceutical composition containing same, a preparation method therefor, and the use thereof as an RIPK1 inhibitor. The compound is a compound as represented by formula (I), or an optical ...
WO/2024/012469A1	CARBAZOLE DERIVATIVE AND USE THEREOF IN ORGANIC LIGHT-EMITTING ELEMENT The present invention relates to a carbazole derivative and use thereof in an organic light-emitting element. The carbazole derivative has a fused carbazole structure, a high triplet state energy level is achieved, and conjugation of a c...
WO/2024/012572A1	PHARMACEUTICAL COMPOSITION OF HETEROARYL DERIVATIVE AND MEDICAL USE THEREOF A pharmaceutical composition or a pharmaceutical preparation, the pharmaceutical composition or the pharmaceutical preparation comprising a therapeutically effective amount of an active ingredient M and a pharmaceutically acceptable exci...
WO/2024/015731A1	FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS Dislcosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or dis...
WO/2023/280638A9	VINYL THIANTHRENIUM COMPOUND, PROCESS FOR ITS PREPARATION AND ITS USE FOR TRANSFERRING A VINYL GROUP The application relates to vinyl thianthrenium compounds Vinyl- TT+X- of the Formula (I), a process for preparing the same and the use thereof for vinylating organic compounds.
WO/2024/012543A1	COMPOUND USED AS CDK4 INHIBITOR AND USE THEREOF Disclosed are a compound used as a cyclin-dependent kinase (CDK) 4 (CDK4) inhibitor and a use thereof. The specifically disclosed compound has a structure represented by formula I, wherein the definitions of groups and substituents are a...

Matches 351 - 400 out of 36,990	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >